Research ExplorerPublicationsSurvival benefit of local versus no local treatment for meta...

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages

Standard

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. / Pompe, Raisa S; Tilki, Derya; Preisser, Felix; Leyh-Bannurah, Sami-Ramzi; Bandini, Marco; Marchioni, Michele; Gild, Philipp; Tian, Zhe; Fossati, Nicola; Cindolo, Luca; Shariat, Shahrokh F; Huland, Hartwig; Graefen, Markus; Briganti, Alberto; Karakiewicz, Pierre I.

In: PROSTATE, Vol. 78, No. 10, 07.2018, p. 753-757.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pompe, RS, Tilki, D, Preisser, F, Leyh-Bannurah, S-R, Bandini, M, Marchioni, M, Gild, P, Tian, Z, Fossati, N, Cindolo, L, Shariat, SF, Huland, H, Graefen, M, Briganti, A & Karakiewicz, PI 2018, 'Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages', PROSTATE, vol. 78, no. 10, pp. 753-757. https://doi.org/10.1002/pros.23519

APA

Pompe, R. S., Tilki, D., Preisser, F., Leyh-Bannurah, S-R., Bandini, M., Marchioni, M., Gild, P., Tian, Z., Fossati, N., Cindolo, L., Shariat, S. F., Huland, H., Graefen, M., Briganti, A., & Karakiewicz, P. I. (2018). Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. PROSTATE, 78(10), 753-757. https://doi.org/10.1002/pros.23519

Vancouver

Pompe RS, Tilki D, Preisser F, Leyh-Bannurah S-R, Bandini M, Marchioni M et al. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. PROSTATE. 2018 Jul;78(10):753-757. https://doi.org/10.1002/pros.23519

Bibtex

@article{c476aeb7ef1947e096a483ba0baa9b83,
title = "Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages",
abstract = "BACKGROUND: To test whether local treatment (LT), namely radical prostatectomy (RP) or brachytherapy (BT) still confers a survival benefit versus no local treatment (NLT), when adjusted for baseline PSA (bPSA). To further examine whether the effect of LT might be modulated according to bPSA and M1 substages.METHODS: Of 13 906 mPCa patients within the SEER (2004-2014), 375 underwent RP, 175 BT, and 13 356 NLT. Multivariable competing risks regression (MVA CRR) analyses after 1:2 propensity score matching assessed the impact of LT versus NLT on cancer specific mortality (CSM). Interaction analyses tested the association between treatment type and bPSA within different M1 substages.RESULTS: MVA CRR analyses revealed lower CSM rates for LT (RP [HR: 0.55, CI: 0.44-0.70, P < 0.001] and BT [HR: 0.63, CI: 0.49-0.83, P < 0.001]) compared to NLT. A significant interaction existed between bPSA and treatment type, in M1b patients only. Here, LT conferred a survival benefit when bPSA was <60 ng/mL with maximum benefit when bPSA was <40 ng/mL. No survival benefit existed for M1b patients above the 60 ng/mL bPSA threshold and for M1c patients, regardless of bPSA. For M1a patients, LT conferred a survival benefit compared to NLT. However, dose-response according to bPSA could not be tested, due to insufficient sample size.CONCLUSIONS: Our observations provide new insight regarding the pivotal effect of bPSA and M1 substages on CSM, when LT is contemplated. While M1a patients benefited from LT, the survival benefit was modulated by bPSA in M1b patients and no survival benefit existed in M1c patients.",
keywords = "Journal Article",
author = "Pompe, {Raisa S} and Derya Tilki and Felix Preisser and Sami-Ramzi Leyh-Bannurah and Marco Bandini and Michele Marchioni and Philipp Gild and Zhe Tian and Nicola Fossati and Luca Cindolo and Shariat, {Shahrokh F} and Hartwig Huland and Markus Graefen and Alberto Briganti and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = jul,
doi = "10.1002/pros.23519",
language = "English",
volume = "78",
pages = "753--757",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages

AU - Pompe, Raisa S

AU - Tilki, Derya

AU - Preisser, Felix

AU - Leyh-Bannurah, Sami-Ramzi

AU - Bandini, Marco

AU - Marchioni, Michele

AU - Gild, Philipp

AU - Tian, Zhe

AU - Fossati, Nicola

AU - Cindolo, Luca

AU - Shariat, Shahrokh F

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/7

Y1 - 2018/7

N2 - BACKGROUND: To test whether local treatment (LT), namely radical prostatectomy (RP) or brachytherapy (BT) still confers a survival benefit versus no local treatment (NLT), when adjusted for baseline PSA (bPSA). To further examine whether the effect of LT might be modulated according to bPSA and M1 substages.METHODS: Of 13 906 mPCa patients within the SEER (2004-2014), 375 underwent RP, 175 BT, and 13 356 NLT. Multivariable competing risks regression (MVA CRR) analyses after 1:2 propensity score matching assessed the impact of LT versus NLT on cancer specific mortality (CSM). Interaction analyses tested the association between treatment type and bPSA within different M1 substages.RESULTS: MVA CRR analyses revealed lower CSM rates for LT (RP [HR: 0.55, CI: 0.44-0.70, P < 0.001] and BT [HR: 0.63, CI: 0.49-0.83, P < 0.001]) compared to NLT. A significant interaction existed between bPSA and treatment type, in M1b patients only. Here, LT conferred a survival benefit when bPSA was <60 ng/mL with maximum benefit when bPSA was <40 ng/mL. No survival benefit existed for M1b patients above the 60 ng/mL bPSA threshold and for M1c patients, regardless of bPSA. For M1a patients, LT conferred a survival benefit compared to NLT. However, dose-response according to bPSA could not be tested, due to insufficient sample size.CONCLUSIONS: Our observations provide new insight regarding the pivotal effect of bPSA and M1 substages on CSM, when LT is contemplated. While M1a patients benefited from LT, the survival benefit was modulated by bPSA in M1b patients and no survival benefit existed in M1c patients.

AB - BACKGROUND: To test whether local treatment (LT), namely radical prostatectomy (RP) or brachytherapy (BT) still confers a survival benefit versus no local treatment (NLT), when adjusted for baseline PSA (bPSA). To further examine whether the effect of LT might be modulated according to bPSA and M1 substages.METHODS: Of 13 906 mPCa patients within the SEER (2004-2014), 375 underwent RP, 175 BT, and 13 356 NLT. Multivariable competing risks regression (MVA CRR) analyses after 1:2 propensity score matching assessed the impact of LT versus NLT on cancer specific mortality (CSM). Interaction analyses tested the association between treatment type and bPSA within different M1 substages.RESULTS: MVA CRR analyses revealed lower CSM rates for LT (RP [HR: 0.55, CI: 0.44-0.70, P < 0.001] and BT [HR: 0.63, CI: 0.49-0.83, P < 0.001]) compared to NLT. A significant interaction existed between bPSA and treatment type, in M1b patients only. Here, LT conferred a survival benefit when bPSA was <60 ng/mL with maximum benefit when bPSA was <40 ng/mL. No survival benefit existed for M1b patients above the 60 ng/mL bPSA threshold and for M1c patients, regardless of bPSA. For M1a patients, LT conferred a survival benefit compared to NLT. However, dose-response according to bPSA could not be tested, due to insufficient sample size.CONCLUSIONS: Our observations provide new insight regarding the pivotal effect of bPSA and M1 substages on CSM, when LT is contemplated. While M1a patients benefited from LT, the survival benefit was modulated by bPSA in M1b patients and no survival benefit existed in M1c patients.

KW - Journal Article

U2 - 10.1002/pros.23519

DO - 10.1002/pros.23519

M3 - SCORING: Journal article

C2 - 29663462

VL - 78

SP - 753

EP - 757

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 10

ER -